Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

LivaNova's Vagus Nerve Stimulator Earns CE Mark For Treating Depression

Executive Summary

LivaNova announced its vagus nerve stimulator for depression earned the CE mark and said that marketing efforts will be limited in the EU and US.

You may also be interested in...



NICE Updates Neurostim Guidance For Depression, Epilepsy

Special arrangements are needed for VNS for treatment-resistant depression and DBS of the anterior thalamus for refractory epilepsy.

Wall Street Tries To Guess The Impact Of Pandemic On Medtech Revenues

As the pandemic unfolds with an uncertain outcome, US securities analysts that cover publicly traded medtech companies are developing mathematical models to estimate the impact of the COVID-19 pandemic on medtech companies.

LivaNova Launches RECOVER Trial Of VNS For Depression To Meet CMS CED Requirement

LivaNova's RECOVER trial will randomize about 1,000 patients with treatment-resistant depression to either LivaNova’s vagus nerve stimulation therapy or a sham therapy and follow them for at least a year.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT126369

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel